tirzepatide death Tirzepatide reduces albuminuria among adults with type 2 diabetes in SURPASS trials

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death:

20.51

★★★★☆4.8 (126)

SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I

25.12

★★★★★4.9 (98)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

23.57

★★★★★5.0 (157)

GROUNDBREAKING UPDATE! FDA has approved TIRZEPATIDE, a pioneering obesity treatment activating GIP & GLP-1 receptors, for weight loss! Previously, Tirzepatide has been FDA approved for type 2 diabetes as Mounjaro, and although

21.57

★★★★★4.7 (84)

Tirzepatide Matches Dulaglutide in Heart Protection and Cuts Death Risk in Diabetes Trial

28.92

★★★★★4.9 (203)

🚨 New real-world data from #ESC2025: 📉 semaglutide 2.4 mg cuts risk of heart attack, stroke or death by 57% vs. tirzepatide in people with obesity & CVD. 🧬 Benefits appear specific

29.78

★★★★★5.0 (176)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

28.83

★★★★★4.8 (132)